Spero Therapeutics (SPRO) EV to CFO (2023 - 2026)
Spero Therapeutics' EV to CFO was 3.97 in Q2 2026, down 63.8% from the prior quarter.
Powered by 
Analysis
Spero Therapeutics (SPRO) EV to CFO (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Spero Therapeutics' EV to CFO was -3.44 through Jun 30, 2026.
- The Q2 2026 figure marks the lowest quarterly EV to CFO since Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Spero Therapeutics | 68.40 Mn | -127.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.97 |
| Mar 31, 2026 | 10.96 |
| Sep 30, 2023 | -1.02 |
| Jun 30, 2023 | -0.12 |
| Mar 31, 2023 | -2.62 |
API Access
Spero Therapeutics EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=SPRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "SPRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=SPRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();